Endocrine oncology (Bristol, England)最新文献

{"title":"Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study.","authors":"T U Kars,&nbsp;M Kulaksızoğlu,&nbsp;I Kılınç","doi":"10.1530/EO-21-0005","DOIUrl":"https://doi.org/10.1530/EO-21-0005","url":null,"abstract":"<p><strong>Objective: </strong>Thyroid cancer can be detected in 5-10% of patients with thyroid nodules. Management may be a challenge if fine-needle aspiration biopsy yields Bethesda III findings. Most of these cases undergo surgery and are ultimately found benign. Our aim was to evaluate whether serum osteopontin can accurately estimate thyroid cancer risk in cases with cytologically Bethesda III thyroid nodules and, thereby, decrease the number of unnecessary surgical interventions.</p><p><strong>Design and methods: </strong>We obtained blood samples of cases with repeated cytologically Bethesda III thyroid nodules before surgery, and followed up the pathology results after thyroidectomy. We evaluated serum osteopontin from 36 patients with papillary thyroid cancer and compared them with 40 benign cases.</p><p><strong>Results: </strong>Serum osteopontin levels in patients with papillary thyroid cancer are significantly higher than in benign cases (mean serum osteopontin: 10.48 ± 3.51 ng/mL vs6.14 ± 2.29 ng/mL, <i>P</i> < 0.001). The area under the receiver operating characteristics curve was 0.851, suggesting that serum osteopontin could have considerable discriminative performance.</p><p><strong>Conclusions: </strong>In our preliminary study, high serum osteopontin levels can predict the risk of papillary thyroid cancer in thyroid nodules with Bethesda III cytology. Further studies are necessary to confirm these findings.</p>","PeriodicalId":72907,"journal":{"name":"Endocrine oncology (Bristol, England)","volume":"1 1","pages":"17-22"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9818424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"cfDNA in pancreatic neuroendocrine carcinoma management with Cushing's syndrome.","authors":"Laura Gerard,&nbsp;David Barthelemy,&nbsp;Arnaud Gauthier,&nbsp;Valerie Hervieu,&nbsp;Jonathan Lopez,&nbsp;Benjamin Gibert,&nbsp;Helene Lasolle,&nbsp;Laurence Chardon,&nbsp;Jessica Garcia,&nbsp;Gérald Raverot,&nbsp;Léa Payen,&nbsp;Thomas Walter","doi":"10.1530/EO-21-0012","DOIUrl":"https://doi.org/10.1530/EO-21-0012","url":null,"abstract":"<p><strong>Summary: </strong>We report a case of metastatic pancreatic neuroendocrine carcinoma associated with paraneoplastic Cushing's syndrome, successively treated with five lines of treatment (platin-etoposide, LV5FU2-dacarbazine, FOLFIRINOX, pembrolizumab, and paclitaxel) and anti-secretory treatment. Circulating-free DNA (cfDNA) was analysed at each morphological evaluation starting from the second-line treatment. cfDNA changes were well correlated with the disease course, and cfDNA may be used as a predictive marker and/or as an early marker of response. In addition, the absolute count of atypical cells was elevated upon disease progression.</p><p><strong>Learning points: </strong>cfDNA changes were well correlated with the Cushing's syndrome course and with the tumour burden changes assessed by laboratory markers and by RECIST criteria.cfDNA analysis was used to determine the pharmacogenetic patterns of the present patient.An elevated number of atypical circulating cells was noticed upon disease progression.</p>","PeriodicalId":72907,"journal":{"name":"Endocrine oncology (Bristol, England)","volume":"1 1","pages":"K1-K6"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/b4/EO-21-0012.PMC10265538.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9815807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>FOXE1</i> polymorphism rs965513 predisposes to thyroid cancer in a European cohort.","authors":"Patrick W Owens,&nbsp;Terri Patricia McVeigh,&nbsp;Nicola Miller,&nbsp;Carole Guerin,&nbsp;Frederic Sebag,&nbsp;Denis Quill,&nbsp;Marcia Bell,&nbsp;Michael J Kerin,&nbsp;Aoife J Lowery","doi":"10.1530/EO-21-0003","DOIUrl":"https://doi.org/10.1530/EO-21-0003","url":null,"abstract":"<p><strong>Objective: </strong><i>FOXE1</i> is an intronless gene on chromosome 9 which plays a significant role in thyroid morphogenesis. Mutations in <i>FOXE1</i> are associated with thyroid phenotypes including congenital hypothyroidism, thyroid dysgenesis and thyroid cancer. This study aims to investigate the frequency and impact of a SNP (rs965513, G>A) at 9q22.23 in a Western European cohort of patients with differentiated thyroid cancer(DTC), compared to controls.</p><p><strong>Design: </strong>This is a candidate gene case control study.</p><p><strong>Methods: </strong>277 patients with histologically confirmed DTC were recruited from tertiary referral centres in Ireland and France. 309 cancer-free controls were recruited from the community. DNA was extracted from buccal swabs or whole blood of control subjects and patients with DTC. Allelic and genotypic frequencies among patients were compared with controls, to assess the risk for disease conferred by homozygous and heterozygous carriers compared to WT genotypes. Genotyping was performed using Taqman-based PCR.</p><p><strong>Results: </strong>277 patients with confirmed DTC and 309 non-cancer controls were genotyped for the variant (rs965513). The frequency of the minor allele among cases was 0.45 compared to 0.34 among controls. The genotypic odds ratio for heterozygotes was 1.66 (CI 1.16-2.39, <i>P</i> =0.00555), increasing to 2.93 (CI 1.70-5.05, <i>P</i> =0.00007) for rare homozygotes. All subjects were in Hardy-Weinberg equilibrium (±<i>χ</i>², <i>P</i> =0.09, <i>P</i> =0.07 respectively).</p><p><strong>Conclusions: </strong>This <i>FOXE1</i> polymorphism is a low penetrance variant associated with DTC susceptibility in this cohort. The minor allele was identified among patients with thyroid cancer significantly more frequently than controls. An allele dosage effect was observed, with rare homozygous genotypes conferring greater risk than heterozygotes.</p>","PeriodicalId":72907,"journal":{"name":"Endocrine oncology (Bristol, England)","volume":"1 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9815808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}